World first use of gene-edited immune cells to treat leukaemia: One year on

30 Mar 2017, 11:17 a.m.

Great Ormond Street Hospital (GOSH) reported a breakthrough application of gene-editing late in 2015 after a team led by NIHR-funded Professor Waseem Qasim and Professor Paul Veys treated an infant with an otherwise incurable form of leukemia.

That experience, and success in a second infant, has now been published in Science Translational Medicine. The cells had been manufactured in the highly-specialised, BRC-supported clean room facility, in collaboration with Dr Martin Pule at University College London Hospital and French Biotech company, Cellectis. This is the most sophisticated version of gene edited cells made to date using TALEN technology.

These gene-edited cells, called CAR-T cells, can effectively induce remission of acute lymphoblastic leukaemia (ALL). However, in some patients – especially infants – it can be hard to manufacture and modify cells directly from the patient. Alternatively, it may be possible to use donor cells from matched allogeneic haematopoietic stem cell donors. In 2015, the team at GOSH used modified T cells from donors, called UCART19 cells, for the first time in humans to treat two infants with extremely aggressive forms of ALL. This treatment led to successful induction of remission which then allowed an allogeneic stem cell transplantation to go ahead.

Over 12 months later both patients are doing well, and the successful application of this technology provides a demonstration of the potential of gene-editing strategies for engineered cell therapies. However, the investigators remain mindful of residual risks of graft-versus-host disease and the likelihood that in some patients the leukaemia will inevitably ‘escape’ immune effects. Phase I trials are underway and aim to treat ten further infants in combination with bone marrow transplantation as part of a company sponsored trial at GOSH. Meanwhile, Professor Qasim’s group, again with BRC support, are moving rapidly to produce the next generation of universal T cells using the next form of gene-editing technology, CRISPR/Cas9.

This work was also highlighted in the Independent.

GOSH patient receives world-first treatment for her 'incurable' T-cell leukaemia

In May 2022, Alyssa, 13 from Leicester, became the first reported patient in the world to receive base-edited T-cells at Great Ormond Street Hospital for Children (GOSH), in collaboration with the UCL Great Ormond Street Institute of Child Health (UCL GOS

Celebrating three years of progress and breakthroughs at the ZCR

We're celebrating three years of the Zayed Centre for Research. That's another year of breakthrough research, with hundreds of clinicians and researchers collaborating to help seriously ill children from across the globe.

Children at GOSH first to receive CRISPR-edited universal T-cells

Researchers at GOSH and UCL GOS ICH are the first to use CRISPR/Cas9 technology to engineer donor T-cells to try to treat seriously ill children with resistant leukaemia

£35 million research boost for GOSH

The National Institute for Health and Care Research (NIHR) has announced that the Great Ormond Street Hospital (GOSH) Biomedical Research Centre (NIHR GOSH BRC) is one of 20 centres from across the country to receive 5-years of funding.